



**PARIS  
MASH  
MEETING**

# **2025 PROGRAM**

**11<sup>TH</sup> EDITION  
SEPTEMBER 11 & 12 2025**

 **INSTITUT  
PASTEUR**

With the partnership of



## Organized by

### Arun Sanyal

Virginia Commonwealth  
University School of Medicine,  
Richmond, Virginia, USA

### Lawrence Serfaty

Nouvel Hôpital Civil  
Hôpitaux Universitaires de Strasbourg,  
Strasbourg, France

## Scientific committee

Jérôme Boursier  
Jean-François Dufour  
Scott Friedman  
Fabio Marra  
Veronica Miller  
Massimo Pinzani  
Vlad Ratziu  
Jörn Schattenberg  
Mohammad S. Siddiqui



**PARIS  
MASH  
MEETING**



**PARIS  
MASH  
MEETING**

September 11 & 12, 2025, Institut Pasteur

**SCIENTIFIC PROGRAM**

**International Think Tank**

**EDITORIAL**

As the **11th edition of the Paris MASH Meeting** unfolds, we continue to push the boundaries of **metabolic health research**.

This year, the spotlight turns to the integration of **Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)** into the **noncommunicable disease spectrum** and its broader implications on global health.

Our program delves into the latest advances in **epidemiology, clinical trials, and translational science**, with a particular focus on **cancer risk, miRNA research, and therapeutic innovations**.

By bringing together **leading international experts**, we aim to foster **cutting-edge discussions and collaborative breakthroughs**.

Join us at the prestigious **Institut Pasteur on September 11-12, 2025**, to explore the future of **MASLD care and research**.

Arun Sanyal & Lawrence Serfaty



# PARIS MASH MEETING

September 11 & 12, 2025, Institut Pasteur

SCIENTIFIC PROGRAM

International Think Tank

## THURSDAY, 11 SEPTEMBER

08:30 - 08:55 AM **WELCOME DESK OPENING**

08:55 - 09:00 AM **Introduction**  
Lawrence Serfaty (France)

### SESSION 1: EPIDEMIOLOGY AND PUBLIC HEALTH

Chairs: Arun Sanyal (USA), Massimo Pinzani (UK)

09:00 - 09:15 AM **Does MASLD contribute to the overall burden of cancer and cancer-related mortality ?**  
Homi Razavi (USA)

09:15 - 09:30 AM **Implications of global policies on noncommunicable diseases for patients with MASLD**  
TBD

09:30 - 09:45 AM **Age-dependent comorbidity profiles and genetic disorders in real world MASLD cohorts**  
Stefano Romeo (Sweden)

09:45 - 10:15 AM **Discussion**

10:15 - 10:45 AM **COFFEE BREAK AND POSTERS**

### SESSION 2: CLINICAL FRONTIERS

Chairs: Jean-François Dufour (Switzerland), Lawrence Serfaty (France)

10:45 - 11:00 PM **Inclusion of cancer screening within MASLD treatment guidelines**  
Jérôme Boursier (France)

11:00 - 11:15 PM **Do patients with MASH develop post-transplant cancers with greater frequency ?**  
Christophe Moreno (Belgium)

11:15 - 11:30 PM **Relevance of MASLD/MASH on kidney transplantation**  
Gaurav Gupta (USA)

11:30 - 12:00 PM **Discussion**

12:00 - 01:00 PM **INDUSTRY SYMPOSIUM**

### PARALLEL LUNCH SESSION

01:00 - 02:45 PM **1 - Assessment of competing risks to guide individualized risk based management strategies in the clinic**  
Michael Roden (Germany) and Vlad Ratziu (France)

01:00 - 02:45 PM **2 - Imaging in MASLD: from diagnosis to monitoring**  
Cyrielle Caussy (France) and Jörn Schattenberg (Germany)

01:00 - 02:45 PM **3 - Clinical Trial Update**  
Mary Rinella (USA) and Raluca Pais (France)



# PARIS MASH MEETING

September 11 & 12, 2025, Institut Pasteur

## SCIENTIFIC PROGRAM

### International Think Tank

#### SESSION 3: CLINICAL HOT TOPICS

Chairs: Fabio Marra (Italy) and TBD

- 02:45 - 03:00 PM **MASH as a driver of colorectal cancer and cancer metastasis**  
Ekihiro Seki (USA)
- 03:00 - 03:15 PM **Hypobetalipoproteinemia and the risk of HCC in the general population**  
Bertrand Cariou (France)
- 03:15 - 03:30 PM **Is tumor-associated fibrosis harmful or beneficial in MASH-HCC?**  
Scott Friedman (USA)
- 03:30 - 04:00 PM **Discussion**

#### 04:00 - 04:30 PM **COFFEE BREAK AND POSTERS**

- 04:30 - 05:00 PM **BASIC SCIENCE LECTURE**  
**Mechanistic implications of MASLD as etiology of HCC on checkpoint inhibitor therapies**  
Chair: Lawrence Serfaty (France)  
Peter Galle (Germany)

#### SESSION 4: TRANSLATIONAL SCIENCE-miRNA

Chairs: Scott Friedman (USA), Frank Tacke (Germany)

- 05:00 - 05:15 PM **RNA isotypes and their relevance in MASLD**  
Stephen Hoang (USA)
- 05:15 - 05:30 PM **miRNA and intrahepatic cell-cell cross talk in MASH progression**  
Pierre-Emmanuel Rautou (France)
- 05:30 - 05:45 PM **miRNA and inter-organ cross-talk in MASLD-metabolic syndrome**  
Saumya Das (USA)
- 05:45 - 06:15 PM **Discussion**

#### 06:15 - 06:25 PM **POSTER AWARD SESSION**



# PARIS MASH MEETING

September 11 & 12, 2025, Institut Pasteur

SCIENTIFIC PROGRAM

International Think Tank

## FRIDAY, 12 SEPTEMBER

### 08:30 - 09:30 AM **SESSION 5: INDUSTRY CORNER**

Chairs : Arun Sanyal (USA), Lawrence Serfaty (France)

#### **Presentations & Round table**

### 09:30 - 10:00 AM **COFFEE BREAK AND POSTERS**

### **SESSION 6: CLINICAL TRIALS**

Chairs: Mary Rinella (USA), Vlad Ratziu (France)

### 10:00 - 10:15 AM **Integrated Trial Design - challenges and opportunities for MASLD to be included in CRM trials**

Faiez Zannad (France)

### 10:15 - 10:30 AM **What is the evidence needed to extend label indication for approved MASH therapies to children ?**

TBD

### 10:30 - 10:45 AM **Design of trials in real-world setting to establish value of MASH therapies**

Natalia Muhlemann (USA)

### 10:45 - 11:15 PM **Discussion**

### 11:15 - 12:15 AM **INDUSTRY SYMPOSIUM**

#### **PARALLEL LUNCH SESSION**

### 12:15 - 02:00 PM **1 - MASLD as a DILI risk factor**

Jean-François Dufour (Switzerland) and TBD

### 12:15 - 02:00 PM **2 - Integrating metabolic to alcohol driven spectrum of steatotic liver disease for clinical care**

Juan Pablo Arab (USA) and Philippe Mathurin (France)

### 12:15 - 02:00 PM **3 - Clinical Challenges**

Laurent Castera (France) and Maud Lemoine (UK)

#### **REGULATORY FORUM SYMPOSIUM**

Chair: Lawrence Serfaty (France)

### 02:00 - 02:15 PM **A progress report on the placebo arm project of the Liver Forum**

Veronica Miller (USA)

### 02:15 - 02:30 PM **FNIH Corner**

Tania Kamphaus (USA)



**PARIS  
MASH  
MEETING**

September 11 & 12, 2025, Institut Pasteur

**SCIENTIFIC PROGRAM**

**International Think Tank**

02:30 - 03:00 PM

**CLINICAL LECTURE**

**Progress in development of a reasonably likely surrogate endpoint for MASH**

Chair: Laurent Castera (France)

Arun Sanyal (USA)

**SESSION 7: MAKING MASLD CARE UNIVERSAL - THE GLOBAL HEALTH CORNER**

Chair: Arun Sanyal (USA)

03:00 - 03:15 PM

**How Latin America is retraining its workforce to manage MASLD**

David Kershenobich (Mexico)

03:15 - 03:30 PM

**Status of MASLD in the UN policy summit on resource allocation for non-communicable diseases**

Johanna Ralston (World Obesity Federation)

03:30 - 03:45 PM

**Role of Journals in increasing awareness and changing practice for MASLD**

Flavia Geraldes (Editor, Lancet)

03:45 - 04:00 PM

**Round table**

04:00 - 04:10 PM

**CONCLUDING REMARKS**



**PARIS  
MASH  
MEETING**

September 11 & 12, 2025, Institut Pasteur

**SCIENTIFIC PROGRAM**

**International Think Tank**

**FACULTY 2025**

**ARAB Juan Pablo**

**BOURSIER Jérôme**

**CARIOU Bertrand**

**CASTERA Laurent**

**CAUSSY Cyrielle**

**CHALASINI Naga**

**DAS Saumya**

**DUFOUR Jean-François**

**FRIEDMAN Scott**

**GALLE Peter**

**DE OLIVEIRA GERALDES Flavia**

**GUPTA Gorav**

**HOANG Stephen**

**KAMPHAUS Tania**

**KERSHENOBICH David**

**LEMOINE Maud**

**MARRA Fabio**

**MATHURIN Philippe**

**MILLER Veronica**

**MORENO Christophe**

**MUHLEMANN Natalia**

**PAIS Raluca**

**PINZANI Massimo**

**RALSTON Johanna**

**RAUTOU Pierre-Emmanuel**

**RAZAVI Homie**

**RATZIU Vlad**

**RINELLA Mary**

**RODEN Michael**

**ROMEO Stefano**

**SANYAL Arun**

**SCHATTENBERG Jörn**

**SEKI Ekihiro**

**SERFATY Lawrence**

**TACKE Frank**

**ZANNAD Faiez**